345 related articles for article (PubMed ID: 26868123)
1. Randomized, blinded trial of vitamin D3 for treating aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).
Shapiro AC; Adlis SA; Robien K; Kirstein MN; Liang S; Richter SA; Lerner RE
Breast Cancer Res Treat; 2016 Feb; 155(3):501-12. PubMed ID: 26868123
[TBL] [Abstract][Full Text] [Related]
2. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
[TBL] [Abstract][Full Text] [Related]
3. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
4. Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study.
Briot K; Tubiana-Hulin M; Bastit L; Kloos I; Roux C
Breast Cancer Res Treat; 2010 Feb; 120(1):127-34. PubMed ID: 20035381
[TBL] [Abstract][Full Text] [Related]
5. Management of aromatase inhibitor induced musculoskeletal symptoms in postmenopausal early Breast cancer: A systematic review and meta-analysis.
Roberts K; Rickett K; Greer R; Woodward N
Crit Rev Oncol Hematol; 2017 Mar; 111():66-80. PubMed ID: 28259297
[TBL] [Abstract][Full Text] [Related]
6. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
[TBL] [Abstract][Full Text] [Related]
7. Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer.
Khan QJ; Reddy PS; Kimler BF; Sharma P; Baxa SE; O'Dea AP; Klemp JR; Fabian CJ
Breast Cancer Res Treat; 2010 Jan; 119(1):111-8. PubMed ID: 19655244
[TBL] [Abstract][Full Text] [Related]
8. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Singh S; Cuzick J; Mesher D; Richmond B; Howell A
Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
[TBL] [Abstract][Full Text] [Related]
9. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis.
Lintermans A; Van Calster B; Van Hoydonck M; Pans S; Verhaeghe J; Westhovens R; Henry NL; Wildiers H; Paridaens R; Dieudonné AS; Leunen K; Morales L; Verschueren K; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
Ann Oncol; 2011 Aug; 22(8):1763-9. PubMed ID: 21273342
[TBL] [Abstract][Full Text] [Related]
10. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
Ganz PA; Cecchini RS; Julian TB; Margolese RG; Costantino JP; Vallow LA; Albain KS; Whitworth PW; Cianfrocca ME; Brufsky AM; Gross HM; Soori GS; Hopkins JO; Fehrenbacher L; Sturtz K; Wozniak TF; Seay TE; Mamounas EP; Wolmark N
Lancet; 2016 Feb; 387(10021):857-65. PubMed ID: 26686960
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of high-dose versus standard-dose vitamin D3 for prevention of aromatase inhibitor-induced arthralgia.
Niravath P; Hilsenbeck SG; Wang T; Jiralerspong S; Nangia J; Pavlick A; Ademuyiwa F; Frith A; Ma C; Park H; Rigden C; Suresh R; Ellis M; Kent Osborne C; Rimawi MF
Breast Cancer Res Treat; 2019 Sep; 177(2):427-435. PubMed ID: 31218477
[TBL] [Abstract][Full Text] [Related]
13. Single arm phase II study of oral vitamin B12 for the treatment of musculoskeletal symptoms associated with aromatase inhibitors in women with early stage breast cancer.
Campbell A; Heydarian R; Ochoa C; Dwivedi AK; Nahleh ZA
Breast J; 2018 May; 24(3):260-268. PubMed ID: 29442401
[TBL] [Abstract][Full Text] [Related]
14. Vitamin D deficiency and bone mineral density in postmenopausal women receiving aromatase inhibitors for early breast cancer.
Nogues X; Servitja S; Peña MJ; Prieto-Alhambra D; Nadal R; Mellibovsky L; Albanell J; Diez-Perez A; Tusquets I
Maturitas; 2010 Jul; 66(3):291-7. PubMed ID: 20399042
[TBL] [Abstract][Full Text] [Related]
15. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
16. A randomized, double-blind, placebo-controlled trial of testosterone for treatment of postmenopausal women with aromatase inhibitor-induced arthralgias: Alliance study A221102.
Cathcart-Rake E; Novotny P; Leon-Ferre R; Le-Rademacher J; Storrick EM; Adjei AA; Terstriep S; Glaser R; Giuliano A; Mitchell WR; Page S; Austin C; Deming RL; Ferreira MA; Lafky JM; Birrell SN; Loprinzi CL
Support Care Cancer; 2021 Jan; 29(1):387-396. PubMed ID: 32372176
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.
Sendur MA; Aksoy S; Zengin N; Altundag K
J BUON; 2013; 18(4):838-44. PubMed ID: 24344006
[TBL] [Abstract][Full Text] [Related]
18. Effects of vitamin D and calcium supplementation on side effects profile in patients of breast cancer treated with letrozole.
Arul Vijaya Vani S; Ananthanarayanan PH; Kadambari D; Harichandrakumar KT; Niranjjan R; Nandeesha H
Clin Chim Acta; 2016 Aug; 459():53-56. PubMed ID: 27221206
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
Waltman NL; Ott CD; Twiss JJ; Gross GJ; Lindsey AM
Cancer Nurs; 2009; 32(2):143-50. PubMed ID: 19125120
[TBL] [Abstract][Full Text] [Related]
20. A prospective study of aromatase inhibitor-associated musculoskeletal symptoms and abnormalities on serial high-resolution wrist ultrasonography.
Henry NL; Jacobson JA; Banerjee M; Hayden J; Smerage JB; Van Poznak C; Storniolo AM; Stearns V; Hayes DF
Cancer; 2010 Sep; 116(18):4360-7. PubMed ID: 20549827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
